The 22 June 2016 the subscription period in ExpreS2ion Biotech Holding AB’s (”ExpreS2ion”) initial public offering (”IPO”) of shares at Nasdaq Stockholm First North (”First North”) ended. The IPO was subscribed for approximately 19.2 MSEK inclusive subscription commitments, corresponding to a subscription rate of approximately 107 percent. Through the IPO ExpreS2ion gets approximately 440 new share owners and approximately 18 MSEK before emission costs. The first day of trading is expected to be the 27 July 2016.
Subscription and allotment
The IPO was subscribed at approximately 19.2 MSEK including subscription commitments, corresponding to a subscription rate of approximately 107 percent. Hence the issued guarantee commitments were not activated. Through the IPO, 3 050 000 shares have been issued. ExpreS2ion has therefore raised approximately 18 MSEK before emission costs of approximately 1.4 MSEK. Settlement notes are planned to be sent out today the 29 June 2016.